A randomized, double-blinded, placebo-controlled trial to assess the antidepressant effects of the NMDA antagonist, CP-101 606 [traxoprodil], in patients with treatment refractory major depressive disorder

Trial Profile

A randomized, double-blinded, placebo-controlled trial to assess the antidepressant effects of the NMDA antagonist, CP-101 606 [traxoprodil], in patients with treatment refractory major depressive disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2008

At a glance

  • Drugs Paroxetine; Traxoprodil
  • Indications Depression; Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2008 Results were published in the Journal of Clinical Psychopharmacology.
    • 02 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top